TP53 and breast carcinoma: MAP was found to be methodologically robust when utilized i) to detect EGFR mutations in lung tissue or ii) to detect p53 breast cancer signatures in plasma and the cellular compartments of blood or iii) to screen for mosaicism for common EGFR mutations in a large population.